News

Comphya adds top clinicians as advisors

Comphya adds top clinicians as advisors

29 September 2022

PRESS RELEASE A pioneer in robotic surgery and two leading authorities in men’s sexual health join Comphya’s Clinical Advisory Board. This gives the startup a...

Read more
Low-intensity electrostimulation reestablishes erectile function after prostatectomy

Low-intensity electrostimulation reestablishes erectile function after prostatectomy

16 March 2022

PRESS RELEASE A study published in the Journal of Sexual Medicine shows that Comphya’s implantable neurostimulator does not only allow on-demand penile erection, but could...

Read more
Comphya announces that two new patents have been granted in the U.S. for the CaverSTIM system

Comphya announces that two new patents have been granted in the U.S. for the CaverSTIM system

02 December 2021

PRESS RELEASE Lausanne, Switzerland, December 02nd, 2021. Comphya SA, a medical device company focusing on the treatment of erectile dysfunction by neuromodulation for non-responders to...

Read more
Comphya has received ISO 13485 certification for the design, development, manufacture and sterilization

Comphya has received ISO 13485 certification for the design, development, manufacture and sterilization

28 October 2021

PRESS RELEASE Lausanne, Switzerland, October 28th, 2021. Comphya announces that it has received the ISO 13485 certificate for Medical Device and Quality Management Systems. The...

Read more
Comphya strengthens its team with the appointment of Pierre Chauvineau as new Board of Director

Comphya strengthens its team with the appointment of Pierre Chauvineau as new Board of Director

10 February 2021

PRESS RELEASE Lausanne, Switzerland, February 10th, 2021. Comphya SA, the developer of CaverSTIM, the first implantable neurostimulator to restore erectile function in non-responders to oral...

Read more
Comphya raises additional USD 1.3 million to secure the execution of the pilot clinical trials to start early 2021

Comphya raises additional USD 1.3 million to secure the execution of the pilot clinical trials to start early 2021

01 December 2020

PRESS RELEASE Lausanne, Switzerland, December 01st, 2020. Comphya SA, a developer of the first neuromodulator to treat erectile dysfunction, today announced the fundraising of USD...

Read more
CaverSTIM system is now powered by ACCEL+ IPG platform.

CaverSTIM system is now powered by ACCEL+ IPG platform.

21 October 2020

PRESS RELEASE Lausanne, Switzerland, October 21th, 2020. Comphya SA, the developer of CaverSTIM, and Cirtec Medical Corp. today announced their decision to transfer the development...

Read more
Comphya appoints Mikael Sturny as Chief Technology Officer.

Comphya appoints Mikael Sturny as Chief Technology Officer.

02 October 2020

PRESS RELEASE Lausanne, Switzerland, September 22, 2020 -  Comphya SA, the developer of CaverSTIM, announced today the appointment of Mikael Sturny as Chief Technology Officer....

Read more
Comphya Clinical Advisory Board in a Meeting

Comphya is delighted to announce the formation of the Clinical Advisory Board

10 February 2020

PRESS RELEASE Lausanne, Switzerland, February 07th, 2020 - Comphya SA, the developer of CaverSTIM™, the first implantable neurostimulator to restore erectile function in non-responders to...

Read more
Comphya SA and Cirtec Medical Corp. announce the partnership on the development of CaverSTIM

Comphya SA and Cirtec Medical Corp. announce the partnership on the development of CaverSTIM

25 October 2019

PRESS RELEASE Comphya SA announces partnership with Cirtec Medical Corp. on the development of the first implantable neurostimulator to treat Erectile Dysfunction. Lausanne, Switzerland, October...

Read more